Thank a tous. and the on for good for press the the the morning. can for business for of discuss afternoon, financial us XXXX update yesterday financial quarter to first business and our you. joining business our and highlights call the presentation financials third of Thank Good you page months update nine Relations webcast and Investor of release the our announced be the this found year. We and evening, website. Bonjour
And Slide X, all involve you and to to the have the differ know, uncertainties usual, I risks disclaimer actual X, cause Slide that to to agenda. statements. draw remind results you Turning call timings as starting attention materially. today's and to before they your that could as forward-looking includes
us update After balance, the Officer, lines the our for which, financials will on El-Hariry key a we recent that call highlights Officer. more Iman be I introduction the up summarize At today start Dr. before Soyer, in Joining year-to-date, the will of and open business Operating ones, the Financial will present ones and present. Eric present the an me Q&A occurred Chief all short and the also on last Chief are Medical key cash call on he Eric with after Chief September. of three our focusing our will and expected which our milestones
cell the know, ERYTECH, focused therapeutics. name for overview most or you completeness, with for blood development is it's based this and company really but Slide So update an says the red of an anyone think to of I on ERYTECH, the new X
programs of with preclinical and now programs. encapsulation, will are -- results blood pursue the the been and in on now the the The field in have eryaspase Slide lymphoblastic, Quickly in in on is -- decided red for is red is this slide, these product. still from of preclinical time working acute active loaded as developed and further a asparaginase ALL which the diseases, point Focus this lymphoblastic the working in preclinical platform, be options for capsulated vesicles recently encouraging items We're minute. a next also proof pursuing to our rare leukaemia But blood more ERYCAPS derived main to quarter the cells, clearly with but this and have have with then news which had third on this cells, and not priority highlights. business the development we the in and year-to-date. pancreatic cancer. other we some partnering focused X, quite concept from product We
it indication this the and feedback competitive that on context for was task FDA, the needed this whole we had from just of clinical the an environment, which And which U.S. first activities The of that was we obtain is in and presented in August, an one try our last pursue to ALL. Graspa largely decided fact the became based specific we in data, us. ALL indeed received no for impossible sub already been longer at to additional approval subsegment call hypersensitive a our clear for in was
cancer trial of safety efficacy a with to now. prematurely, should together was or but there the said baseline the It an the that of X development Phase this decision there This the -- then just results no trial. year one, still in steering the the that eryaspase of the stopped last the combined presented that saw a activity. triple a because of small good cancer, pancreatic end The And but we negative September of committee trial company priorities Phase X stop in at we number Another took signal. breast Graspa was sort not in this which continue had we was also earlier we which was setback was of TRYbeCA-X altogether. in single patients this
mainly all, a also cost the in and France, the plan, reductions staff sale the which we a deep restructuring of U.S. reduction the plan We've restructuring, not launched news, of already, as have had we performed as facility, and Princeton implemented have First now cost this restructuring. soon implemented. the [indiscernible] fully is in but after
to Phase the X still the the compared of that number now at is at year, small, less than trial, are team we end implementation, so of we at so announced but time, last people time, roughly steep end which And reduction of at a the XX%, now, pancreatic the size. of
promise on and the extracellular exosome of have the so The we like, on the our especially activities, gene our delivery. priority a XX-XX where applications, core people kept derived in second non-viral we or remaining priority the red we XX-ish for now other focusing R&D lot programs company and it's from second vesicles, the immuneoncology see preclinical team the and cells, for of where also potentially but held, the vesicles, for RNA a
work we beginning working in-vivo in of we next that quarter in past provide to the In-vivo and programs the We're to rare months or already in-vitro on We able first had. ongoing the expect have disease shown is -- be year. update an over visibility. also
announced results main for a lead it third that but of the and realized offer, them the first were next the X Also renewed while be we've search already did rare We've then still year. is company provide updates they to renewed priority a we it options. strategic in And anymore. quarter able much every lot the fact, the re working so has expect doesn't get of but were to not In on Graspa programs trial attention, here of -- now tech disease attention. giving we're sort after Phase to program is giving have reviving
We've also we're GMP core company to that Eric coming in is on listed an do corporate months. here production few can facility was the first research technology, hope end update, Princeton on of cash. broad with zoomed We in least And options working sale to ERYTECH a at team provide support trying and Catalent valuable year or on core What with a to such will recapitalize the and in to the are combination. infrastructure an the of being before options. did IP which the a still step. provide able company update a screening. different a we -- be a team, facility, now our a So U.S. a the facility
for first it the here I nine who for will And that's X we'll update the news flow the will the Eric, over for the Slide to So on an yours. stop highlights. and financials summarize months. afterwards. hand Eric, provide all
